MacroGenics Inc. expanded its board to eight members and appointed Karen Ferrante and Scott Jackson to fill the new vacancies.

Ferrante, who recently served as chief medical officer and head of research and development at Tokai Pharmaceuticals Inc., will serve on the MacroGenics nominating & corporate governance committee. Jackson, who previously served as CEO of Celator Pharmaceuticals Inc., will sit on the compensation committee.